INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 414m ago
HOUSE PTR13m ago
SEC 13F13m ago
ROBINHOOD CHAIN13m ago
Public company

XERSXeris Biopharma Holdings, Inc.

CIK 0001867096

EDGAR filingsOpen in network
Disclosed transactions40
Buys / sells0 / 13
Max Insider Score25
Connections10with evidence

XERS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
TM
Taddese MenassieDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award
A$320K
31.5K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Hecht BethSee Remarks · Nov 4, 2026
  • ← Insider ofevidence
    Taddese MenassieDirector · Nov 4, 2026
  • ← Insider ofevidence
    Shannon John Patrick JrDirector, See Remarks · Aug 21, 2026
21
HB
Hecht BethSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL
$256K
25.0K sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

14
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$153K
15.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

14
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$51K
5,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

9
TM
Taddese MenassieDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
22.4K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

7
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$250K
25.0K sh
Sep 28, 2026Sep 29, 2026
traded Sep 28, 2026
+1dSEC FORM 4

Evidence

9
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$127K
15.0K sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

6
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$43K
5,000 sh
Sep 1, 2026Sep 1, 2026
traded Sep 1, 2026
+0dSEC FORM 4

Evidence

18
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$177K
21.9K sh
Aug 1, 2026Aug 21, 2026
traded Aug 1, 2026
+20dSEC FORM 4

Evidence

25
SP
Shannon John Patrick JrDirector, See Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$296K
36.6K sh
Aug 1, 2026Aug 21, 2026
traded Aug 1, 2026
+20dSEC FORM 4

Evidence

1
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$43K
5,000 sh
Aug 12, 2026Aug 12, 2026
traded Aug 12, 2026
+0dSEC FORM 4

Evidence

9
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$235K
27.6K sh
Jul 7, 2026Jul 7, 2026
traded Jul 7, 2026
+0dSEC FORM 4

Evidence

13
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$148K
17.4K sh
Jul 6, 2026Jul 7, 2026
traded Jul 6, 2026
+1dSEC FORM 4

Evidence

16
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$723K
90.0K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

0
PM
Persky MarlaDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award · 10b5-1 plan
A—
24.2K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

13
BA
Brady James AloysiusDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
24.2K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

8
BA
Brady James AloysiusDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award
A$203K
33.0K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

13
KG
Kong GarhengDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
24.2K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

12
KG
Kong GarhengDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award
A$203K
33.0K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

12
PM
Persky MarlaDirector
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$91K
15.5K sh
Jun 3, 2026Jun 5, 2026
traded Jun 3, 2026
+2dSEC FORM 4

Evidence

0
PM
Persky MarlaDirector
XERSXeris Biopharma Holdings, Inc.
Grant or award · 10b5-1 plan
A$203K
33.0K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

12
BA
Brady James AloysiusDirector
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$60K
10.8K sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

8
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Option exercise
M$200K
48.9K sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

5
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Option exercise
M$15.76
4 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

5
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Option exercise
M$15.76
4 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

8
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Option exercise
M$200K
48.9K sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

16
NT
Nguyen Anh TuSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$202K
29.3K sh
Feb 24, 2026Feb 25, 2026
traded Feb 24, 2026
+1dSEC FORM 4

Evidence

13
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
155.0K sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC FORM 4

Evidence

11
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$504K
68.5K sh
Jan 31, 2026Feb 2, 2026
traded Jan 31, 2026
+2dSEC FORM 4

Evidence

9
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
168.5K sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC FORM 4

Evidence

8
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$223K
30.3K sh
Jan 31, 2026Feb 2, 2026
traded Jan 31, 2026
+2dSEC FORM 4

Evidence

5
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
225.2K sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC FORM 4

Evidence

8
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$201K
27.3K sh
Jan 31, 2026Feb 2, 2026
traded Jan 31, 2026
+2dSEC FORM 4

Evidence

19
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$823K
111.8K sh
Jan 31, 2026Feb 2, 2026
traded Jan 31, 2026
+2dSEC FORM 4

Evidence

9
NT
Nguyen Anh TuSee Remarks
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
162.2K sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC FORM 4

Evidence

17
NT
Nguyen Anh TuSee Remarks
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
121.3K sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC FORM 4

Evidence

9
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Grant or award
A—
207.2K sh
Jan 30, 2026Feb 2, 2026
traded Jan 30, 2026
+3dSEC FORM 4

Evidence

12
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$201K
27.3K sh
Jan 31, 2026Feb 2, 2026
traded Jan 31, 2026
+2dSEC FORM 4

Evidence

19
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Tax withholding
F$489K
66.5K sh
Jan 31, 2026Feb 2, 2026
traded Jan 31, 2026
+2dSEC FORM 4

Evidence

8
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$120K
15.0K sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

← Insider ofevidence
Kong Garheng
Director · Jun 5, 2026
  • ← Insider ofevidence
    Persky MarlaDirector · Jun 5, 2026
  • ← Insider ofevidence
    Brady James AloysiusDirector · Apr 1, 2026
  • ← Insider ofevidence
    Pieper StevenSee Remarks · Feb 2, 2026
  • ← Insider ofevidence
    Nguyen Anh TuSee Remarks · Feb 2, 2026
  • ← Insider ofevidence
    McCulloch KevinSee Remarks · Jan 9, 2026